Tianjin Chase Sun Pharmaceutical Co.,Ltd (SHE: 300026)

Market Cap	9.58B
Revenue (ttm)	5.68B
Net Income (ttm)	308.99M
Shares Out	3.00B
EPS (ttm)	0.10
PE Ratio	31.19
Forward PE	17.72
Dividend	0.03 (0.93%)
Ex-Dividend Date	May 23, 2024

Volume	19,307,800
Open	3.260
Previous Close	3.210
Day's Range	3.160 - 3.260
52-Week Range	3.010 - 4.940
Beta	-0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Tianjin Chase Sun Pharmaceutical Co.,Ltd

Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and marketing of various pharmaceutical products in China and internationally. The company offers Chinese medicine granules, finished pharmaceutical products, raw materials and excipients, medical devices, healthcare services, and smart supply chain for pharmaceutical and medical devices. It provides its products in the areas of severe disease, cardiovascular, cerebrovascular system, respiratory system, neurodegenerative, and anti-tumor. The company was f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 5,910
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300026

Financial Performance

In 2023, Tianjin Chase Sun Pharmaceutical Co.,Ltd's revenue was 6.11 billion, a decrease of -8.14% compared to the previous year's 6.65 billion. Earnings were 506.63 million, a decrease of -18.84%.